The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
The cancer field is not immune to the challenges of out-of-network and surprise billing.
The FDA has granted accelerated approval to Tazverik™ (tazemetostat tablets; Epizyme) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
Findings seen among patients <40 years with bone or soft tissue sarcomas, regardless of disease stage.
A “bionic” T cell that is armed with a bispecific antibody but lacks a chimeric antigen receptor showed cytotoxic activity in cancer cell lines.
The chance of missing a disease-causing variant can be as high as 100% across some groups.
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
A single-day, cGMP-compliant manufacturing process to make a cryopreserved drug product, if successful, could dramatically reduce patient wait times.
Patients may find misinformation on websites or social media forums, but doctors can help by recommending reliable sources.